The antimicrobial resistance diagnostics market size is estimated to be USD 3,989.2 million in 2022 and is expected to witness a CAGR of 6.99% during the forecast period 2023-2033. Rise in regulatory approvals of technically advanced and precise diagnostic solutions, surge in collaborations between key market players, and increasing disease burden caused by pathogens are some of the factors contributing to the market growth. Furthermore, rise in the prevalence of infections caused by antimicrobial resistance (AMR), growing regulatory approvals of diagnostic devices and escalating need for technologically advanced diagnostic solutions to manage AMR are other factors supporting the market growth.  However, high price of automated ID/AST systems is expected to hinder the growth.

Rise in regulatory approvals of technically advanced and precise diagnostic solutions is expected to propel the market growth. For instance, Hologic, Inc. introduced a completely automated Novodiag molecular diagnostic solution of Mobidiag Oy in Europe in October 2021 for the on-demand testing of infectious diseases and antimicrobial resistance. The Novodiag system combines real-time PCR and microarray capabilities. Multiple pathogens can be detected using this test from a single sample. Additionally, OpGen, Inc. declared in October 2021 that it had been granted a 50(k) clearance by the U.S. FDA to market the Acuitas AMR Gene Panel.

Surge in collaborations between key market players is predicted to fuel the market growth during the forecast period. For instance, in July 2022, Boehringer Ingelheim, bioMérieux, and Evotec SE established a collaborative venture to create the next generation of antibiotics and useful diagnostics in order to lessen the burden of antimicrobial resistance. As 80% of the entire expenditure will go toward combating AMR, bioMerieux will develop testing methods for antibiotic resistance under the terms of this joint venture.

Segmentation

By Technology

The market is categorized into PCR, microbiology culture, rapid & point of care, NGS, immunoassay, mass spectrometry, and others. In 2022, the PCR segment accounted for the highest revenue share due to the developments in PCR technology and its wide penetration due to its high accuracy. The segment is also growing as a result of PCR tests for HAIs including MRSA and C. difficile being used more frequently. Furthermore, it is anticipated that the availability of strong and cutting-edge product portfolios by top market players will boost segment demand. For instance, Vela Diagnostics’ PathoKey MP UTI ID & AMR PCR Test is a real-time PCR solution for the detection of UTI pathogens and AMR genes. Results for genes that cause resistance to five different antibiotics can be obtained with this test. However, it is anticipated that during the projected time, the rapid and point-of-care segment will have the fastest CAGR. There is an increasing need for PoC and rapid diagnostics due to their benefits, including their fast turnaround time, quick results, and low costs. Demand for the market is also projected to be fueled by the quick diagnostics industry’s diverse product offering and the escalating research into developing rapid diagnostic solutions.

 By Pathogen

The market is categorized into drug resistant campylobacter, drug resistant salmonella, clostridium difficile, drug resistant neisseria gonorrhoeae, drug resistant streptococcus pneumoniae, methicillin resistant staphylococcus aureus, others. In the global market, the methicillin resistant staphylococcus aureus segment accounted for the largest revenue share in 2022 owing to rising prevalence of MRSA in hospital settings. For instance, the CDC reports found that approximately 33% of people have S. aureus on their noses without being sick, and about two out of every 100 of these people get MRSA. Additionally, a rise in the number of regulatory approvals for diagnostic tests to find MRSA is another factor causing the segment to grow. For instance, the U.S. FDA authorised a novel diagnostic test for MRSA detection based on bacteriophage technology in January 2020. Additionally, the Cobas vivoDx MRSA diagnostic test has recently received FDA approval for the quantification of MRSA. Clostridium Difficile is anticipated to contribute the second-highest amount of revenue during the forecast period due to the high incidence rate and growing potential to acquire drug resistance to many medications. Several factors contribute to the development of antibiotic resistance in C. difficile strains, including altered protein expression, the spread of mobile genetic elements, gene mutations, iron metabolism, DNA repair, and biofilm formation.

By End User

The market is divided into pharmaceutical & biotechnology companies, hospitals, diagnostic laboratories, and others. In 2022, the hospitals segment accounted for the largest revenue share owing to rise in hospital-acquired infections, increase in hospitalizations brought on by the high prevalence of AMR infections, lengthened hospital stays, expanding access to novel diagnostic tools, affordability, and improved healthcare coverage. Additionally, pathogenic infections including MRSA, CDI, and DRSP can result in pneumonia, sepsis, bloodstream infections, and surgical site infections. Therefore, the prevalence of pathogen-focused diseases in hospitals also contributes to segment growth. Additionally, a research by BD, Pfizer, and Merck published in April 2022 revealed that an increase in antimicrobial resistance was recorded by over 270 hospitals in the United States. However, in the upcoming years, the diagnostic laboratories segment is anticipated to increase at the fastest rate. It is predicted that the growing prevalence of infectious disorders and laboratory technical developments will fuel segment expansion. Additionally, a high penetration of diagnostic-focused laboratories and reasonably priced services are expected to support market growth.

Regional Markets

In 2022, North America region accounted for the highest revenue in the antimicrobial resistance diagnostics market and is expected to maintain its dominance during the forecast period. This is attributed to the higher risk of developing antibiotic resistance, favorable government policies to combat AMR, and existence of cutting-edge healthcare infrastructure. Additionally, the segment expansion in the upcoming years is likely to be fueled by the existence of major market players and the growth strategies taken. Asia Pacific is anticipated to have the fastest growth rate during the projected period. The region’s expansion is anticipated to be supported by the presence of untapped market potential, a high prevalence of antibiotic resistance, and an increase in demand for affordable diagnostic solutions. Additionally, the region’s huge targeted population, growing geriatric population, and numerous government’s awareness campaigns are all anticipated to contribute to the region’s growth. Additionally, the expansion of the region is expected to be driven by the growth in R&D activities related to the creation of improved diagnostic solutions.

Competitor Insights

Some of the key players operating in the antimicrobial resistance diagnostics market are Abbott, bioMerieux, BD, Accelerate Diagnostics, Inc., F. Hoffmann-La Roche Ltd., Danaher, Vela Diagnostics, Visby Medical, Inc., Molsid, and OpGen.

• For instance, bioMerieux announced the agreement to acquire Specific Diagnostics in April 2022. Its position in the market for antimicrobial resistance tests has improved as a result of this acquisition.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including technology, pathogen, and end user from 2023 to 2033.

Report Scope:

Segmentation: Antimicrobial Resistance Diagnostics Market Report 2022 – 2033

Technology (Revenue, USD Million), 2022 – 2033

• PCR
• Microbiology Culture
• Rapid & Point of Care
• NGS
• Immunoassay
• Mass Spectrometry
• Others

Pathogen (Revenue, USD Million), 2022 – 2033

• Drug Resistant Campylobacter
• Drug Resistant Salmonella
• Clostridium Difficile
• Drug Resistant Neisseria Gonorrhoeae
• Drug Resistant Streptococcus Pneumoniae
• Methicillin Resistant Staphylococcus Aureus
• Others

End user (Revenue, USD Million), 2022 – 2033

• Pharmaceutical & Biotechnology Companies
• Hospitals
• Diagnostic Laboratories
• Others

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA